It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion... Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Get short term trading ideas from the MarketBeat Idea Engine. When is Advaxis' next earnings date? Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.Get daily stock ideas top-performing Wall Street analysts. Find the latest Advaxis, Inc. (ADXS) stock quote, history, news and other vital information to help you with your stock trading and investing. ADXS Stock Summary. All rights reserved. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. View the latest Advaxis Inc. (ADXS) stock price, news, historical charts, analyst ratings and financial information from WSJ. Advaxis had a negative net margin of 13,144.62% and a negative return on equity of 82.46%. Get today's Advaxis Inc stock price and latest ADXS news as well as Advaxis real-time stock quotes, technical analysis, full financials and more. Edited Transcript of ADXS earnings conference call or presentation 11-Jun-20 3:00pm GMT Sign-up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.Advaxis' stock was trading at $0.6666 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Stock Ideas and Recommendations. Learn everything you need to know about successful options trading with this three-part video course.Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:You have already added five stocks to your watchlist. The biotechnology company can be reached via phone at 609-452-9813 or via email at Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. These stocks have paid out triple-digit gains… On the same date… Year after year — for the last decade (look at this week’s Primetime Stock here) The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock.
Please log in to your account or sign up in order to add this asset to your watchlist. Revenue growth over the past 12 months for Advaxis Inc comes in at -98.88%, a number that bests merely 0.61% of the US stocks we're tracking. Get Dylan’s next takeover target right here!Advaxis, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States.
View live ADVAXIS INC chart to track its stock's price action. Learn everything you need to know about successful options trading with this three-part video course.Looking for new stock ideas? Advaxis, Inc. (NASDAQ:ADXS) issued its quarterly earnings results on Thursday, June, 11th. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. As of February 28th, there was short interest totaling 4,160,000 shares, a decline of 12.4% from the February 13th total of 4,750,000 shares. Get daily stock ideas top-performing Wall Street analysts. ET by Emma Court Bull trend intact, latest S&P … Want to see which stocks are moving?
They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. Company insiders that own Advaxis stock include Robert Petit and Roni Appel. Individual investors are making an absolute killing on gold stocks. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. We’ve entered a gold bull market.Advaxis has received 52.72% “underperform” votes from our community.Advaxis does not have a long track record of dividend growth.In the past three months, Advaxis insiders have not sold or bought any company stock.Only 0.26% of the stock of Advaxis is held by insiders.Only 11.24% of the stock of Advaxis is held by institutions.The P/E ratio of Advaxis is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.The P/E ratio of Advaxis is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Advaxis has a P/B Ratio of 0.24.
Advaxis' management team includes the following people: Since then, ADXS stock has decreased by 16.5% and is now trading at $0.5567. All rights reserved.